[
    [
        {
            "time": "",
            "original_text": "市值20强前三季业绩大比拼：上药营收超千亿 恒瑞净利近30亿",
            "features": {
                "keywords": [
                    "市值20强",
                    "前三季业绩",
                    "上药",
                    "营收超千亿",
                    "恒瑞",
                    "净利近30亿"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "市值20强前三季业绩大比拼：上药营收超千亿 恒瑞净利近30亿",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "【东北医药刘舒畅/马云涛】上海医药（601607）三季报：业绩稳健增长，创新研发持续推进",
            "features": {
                "keywords": [
                    "东北医药",
                    "上海医药",
                    "三季报",
                    "业绩稳健增长",
                    "创新研发",
                    "持续推进"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【东北医药刘舒畅/马云涛】上海医药（601607）三季报：业绩稳健增长，创新研发持续推进",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "上海医药2018年三季报点评:商业业务Q3利润增速有所放缓,工业业务表现良好",
            "features": {
                "keywords": [
                    "上海医药",
                    "2018年三季报",
                    "商业业务",
                    "Q3利润增速放缓",
                    "工业业务",
                    "表现良好"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "mixed",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "上海医药2018年三季报点评:商业业务Q3利润增速有所放缓,工业业务表现良好",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        }
    ]
]